Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities

Asia-Pacific Journal of Clinical Oncology

Volumn 13, Issue 4, 2017, Pages 277-288

  Roberts, Kate ^a   Culleton, Vanessa ^a   Lwin, Zarnie ^a,b,c   O'Byrne, Kenneth ^d,e   Hughes, Brett GM ^a,b,c  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

autoimmune; CTLA4; immunotherapy; PD1; PDL1

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; HISTAMINE; IMMUNOGLOBULIN; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; MEPREDNISONE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PREDNISOLONE; PREDNISONE;

ADVERSE DRUG REACTION; ANEMIA; ARTHRALGIA; ASEPTIC MENINGITIS; CANCER IMMUNOTHERAPY; COLITIS; COLONOSCOPY; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; ENCEPHALITIS; EPIDERMOLYSIS; FATIGUE; GUILLAIN BARRE SYNDROME; HEMATOLOGIC DISEASE; HEPATITIS; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MACULOPAPULAR RASH; MALIGNANT NEOPLASM; META ANALYSIS (TOPIC); MYALGIA; MYASTHENIA GRAVIS; MYELITIS; MYOCARDITIS; NEPHRITIS; NEUTROPENIA; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SKIN TOXICITY; TREATMENT WITHDRAWAL; UVEITIS; VITILIGO; GENE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES;

GENES, CDC; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 85023191504     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12698     Document Type: Review

References (66)

1. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166–82.
2. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008; 224: 141–65.
3. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373 (1): 23–34.
4. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372 (26): 2521–32.
5. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372 (4): 320–30.
6. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8): 711–23.
7. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373 (17): 1627–39.
8. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373 (2): 123–35.
9. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373 (19): 1803–13.
10. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016; 387 (10031): 1909–20.
11. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008; 13 (Suppl 4): 2–9.
12. Herbst RS, Baas P, Kim D-W et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387 (10027): 1540–50.
13. Champiat S, Lambotte O, Barreau E et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27 (4): 559–74.
14. Menzies AM, Johnson DB, Ramanujam S et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017; 28 (2): 368–76.
15. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16 (8): 908–18.
16. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30 (21): 2691–97.
17. Langer CJ, Gadgeel SM, Borghaei H et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17 (11): 1497–508.
18. Champiat S, Lambotte O, Barreau E et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27 (4): 559–74.
19. Cooley L, Dendle C, Wolf J et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014; 44 (12b): 1350–63.
20. Horvat TZ, Adel NG, Dang T-O et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33 (28): 3193–8.
21. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 2015; 11 (17): 2471–84.
22. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; 33 (18): 2092–9.
23. Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016; 60: 12–25.
24. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013; 19 (8): 2232–9.
25. Eigentler TK, Hassel JC, Berking C et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016; 45: 7–18.
26. Merck. Pembrolizumab US full prescribing information. 2014. [Accessed April 2017]. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
27. Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. v4.03. [Accessed 14 June 2010]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdf.
28. Nayar N, Briscoe K, Fernandez Penas P. Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother 2016; 39 (3): 149–52.
29. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98 (4): 1361–75.
30. Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV. Immune checkpoint inhibitor related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol 2016; 85 (3): 331–9.
31. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21 (2): 371–81.
32. Min L, Hodi FS, Giobbie-Hurder A et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015; 21 (4): 749–55.
33. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26 (12): 2375–91.
34. Genentech. Atezolizumab US full prescribing information. 2016. [Accessed April 2017]. Available from: http://www.gene.com/download/pdf/tecentriq_prescribing.pdf.
35. Gaudy C, Clévy C, Monestier S et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 2015; 38 (11): e182–e183.
36. Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf 2015; 14 (6): 957–64.
37. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol 2013; 13 (4): 278–80.
38. BMS. Ipilimumab US full prescribing information. 2011. [updated October 2015]. [Accessed March 2017]. Available from: http://packageinserts.bms.com/pi/pi_yervoy.pdf.
39. Eggermont AMM, Chiarion-Sileni V, Grob J-J et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16 (5): 522–30.
40. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16 (4): 375–84.
41. Berman D, Parker SM, Siegel J et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10: 11.
42. BMS. Nivolumab US full prescribing information. 2014. [updated May 2016]. [Accessed April 2017]. Available from: http://packageinserts.bms.com/pi/pi_opdivo.pdf.
43. Coit DG, Thompson JA, Algazi A et al. Melanoma, Version 2., NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016; 14 (4): 450–73.
44. Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med 2015; 40 (11): e528–e529.
45. Di Giacomo AM, Danielli R, Guidoboni M et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58 (8): 1297–306.
46. Naidoo J, Wang X, Woo KM et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017; 35 (7): 709–17.
47. Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2015; 38 (4): 422–30.
48. Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis 2016; 10 (3): 183–93.
49. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33 (18): 2004–12.
50. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373 (3): 288–90.
51. Mazzanti G, Di Sotto A, Vitalone A. Hepatotoxicity of green tea: an update. Arch Toxicol 2015; 89 (8): 1175–91.
52. Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015; 125 (9): 3377–83.
53. Sangro B, Gomez-Martin C, de la Mata M et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59 (1): 81–8.
54. Gardiner D, Lalezari J, Lawitz E et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. Plos One 2013; 8 (5): e63818.
55. Liang TJ, Block TM, McMahon BJ et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015; 62 (6): 1893–908.
56. Rehermann B. HCV in 2015: advances in hepatitis C research and treatment. Nat Rev Gastroenterol Hepatol 2016; 13 (2): 70–2.
57. Cortazar FB, Marrone KA, Troxell ML et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016; 90 (3): 638–47.
58. Izzedine H, Gueutin V, Gharbi C et al. Kidney injuries related to ipilimumab. Invest New Drugs 2014; 32 (4): 769–73.
59. O'Kane GM, Lyons TG, Colleran GC et al. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat 2014; 37 (12): 757–60.
60. Crosson JN, Laird PW, Debiec M, Bergstrom CS, Lawson DH, Yeh S. Vogt–Koyanagi–Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 2015; 38 (2): 80–4.
61. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol 2014; 16 (4): 589–93.
62. Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep 2016, https://doi.org/10.1136/bcr-2016-215012.
63. Nair R, Gheith S, Nair SG. Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. N Engl J Med 2016; 374 (11): 1096–7.
64. Simeone E, Grimaldi AM, Esposito A et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 2014; 8: 240.
65. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365 (18): 1747–8.
66. Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo A-M. Ipilimumab-induced ocular and orbital inflammation—A case series and review of the literature. Ocular Immunol Inflamm 2015; 2: 1–7.